1. Home
  2. ZCMD vs PCSA Comparison

ZCMD vs PCSA Comparison

Compare ZCMD & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zhongchao Inc.

ZCMD

Zhongchao Inc.

N/A

Current Price

$1.78

Market Cap

6.9M

Sector

Real Estate

ML Signal

N/A

Logo Processa Pharmaceuticals Inc.

PCSA

Processa Pharmaceuticals Inc.

HOLD

Current Price

$2.45

Market Cap

6.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZCMD
PCSA
Founded
2012
2011
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9M
6.1M
IPO Year
2019
2012

Fundamental Metrics

Financial Performance
Metric
ZCMD
PCSA
Price
$1.78
$2.45
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
34.8K
33.8K
Earning Date
04-28-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$5,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.18
$0.11
52 Week High
$1.95
$8.88

Technical Indicators

Market Signals
Indicator
ZCMD
PCSA
Relative Strength Index (RSI) 68.14 45.84
Support Level $1.02 $1.96
Resistance Level $1.94 $2.56
Average True Range (ATR) 0.18 0.32
MACD -0.04 -0.06
Stochastic Oscillator 77.23 27.05

Price Performance

Historical Comparison
ZCMD
PCSA

About ZCMD Zhongchao Inc.

ZHONGCHAO Inc is an offshore holding company incorporated in the Cayman Islands. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provide the healthcare information, education, and training services to the healthcare professionals under their MDMOOC brand. It also provide focused patient management services, through Zhongxun IT system and WeChat mini program and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.

About PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Share on Social Networks: